论文部分内容阅读
将63例早期DN患者随机分为格列奎酮联合甘精胰岛素治疗组、常规胰岛素治疗组,比较12周前后的FPG达标时间、HbA1c、UAE的变化及低血糖发生率。结果:联合组血糖达标时间3.4±0.7d,HbA1c 6.5±0.8%;胰岛素组达标时间3.1±0.9d,HbA1c 6.7±1.1%比较没统计学差异。联合组UAE 133±32μg/min,低血糖发生率18.2%,胰岛素组UAE167±37μg/min,低血糖发生率40.6%,有明显差异(P<0.001)。结论:格列奎酮联合甘精胰岛素治疗早期糖尿病肾病,同样有效地控制患者血糖,可降低UAE,且低血糖发生率低。
Sixty-three patients with early stage DN were randomly divided into gliclazide combined with insulin glargine treatment group and conventional insulin treatment group. The FPG compliance time, changes of HbA1c and UAE and the incidence of hypoglycemia before and after 12 weeks were compared. Results: The blood glucose of the combination group reached 3.4 ± 0.7d, HbA1c 6.5 ± 0.8%; the insulin group reached the standard time of 3.1 ± 0.9d, HbA1c 6.7 ± 1.1%, no statistical difference. The combined group had a significant difference (P <0.001) in UAE 133 ± 32μg / min, hypoglycemia incidence 18.2%, insulin group UAE167 ± 37μg / min and hypoglycemia incidence 40.6%. Conclusion: Glenelgone combined with insulin glargine for the treatment of early diabetic nephropathy, the same effective control of blood glucose, can reduce UAE, and low incidence of hypoglycemia.